Raymond James Maintains Outperform Rating for PTC Therapeutics: Here's What You Need To Know

Raymond James Maintains Outperform Rating for PTC Therapeutics: Here’s What You Need To Know

in Stocks

Reading Time: 1 min read

Raymond James has decided to maintain its Outperform rating of PTC Therapeutics (NASDAQ:PTCT) and lower its price target from $58.00 to $55.00.

Shares of PTC Therapeutics are trading down 2.83% over the last 24 hours, at $39.18 per share.

Support authors and subscribe to content

This is premium stuff. Subscribe to read the entire article.

Gain access to all our Premium contents.
More than 100+ articles.

Subscribe Now

Unlock this article and gain permanent access to read it.

Unlock Now